Therapix Biosciences Ltd. (Nasdaq: TRPX) to Ring The Nasdaq Stock Market Opening Bell
June 27 2017 - 10:00AM
What: Therapix Biosciences Ltd.
(Nasdaq:TRPX) (“Therapix”), a specialty clinical-stage
pharmaceutical company specializing in the development of
cannabinoid-based drugs, will visit the Nasdaq MarketSite in Times
Square.
In honor of the occasion, Dr. Elran Haber, Chief
Executive Officer, will ring the Opening Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Wednesday, June 28, 2017 – 9:15 a.m. to
9:30 a.m. ET
Therapix Biosciences Ltd. Contact:Tirth Patel,
Vice President, Investor Relations(646)
653-7035tpatel@edisongroup.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Opening
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market open of your choice.
About Therapix Biosciences Ltd.Therapix
Biosciences Ltd. (Nasdaq:TRPX) is a specialty clinical-stage
pharmaceutical company focused on developing technologies and
therapeutics based on cannabinoid pharmaceuticals. The Company’s
clinical pipeline assets follow a de-risked 505(b)(2) regulatory
pathway benefitting from Therapix’s unique proprietary formulations
based on repurposing an FDA approved synthetic cannabinoid
(dronabinol). Therapix’s lead compound, THX-TS01, is currently in
Phase 2 clinical trials for Tourette’s Syndrome and the Company
intends to initiate a Phase 1 clinical study of THX-ULD01 for the
treatment of Mild Cognitive Impairment, for which no FDA-approved
therapies currently exist. Please visit our website for more
information at www.therapixbio.com.
About Nasdaq:Nasdaq (Nasdaq:NDAQ) is a leading
global provider of trading, clearing, exchange technology, listing,
information and public company services. Through its diverse
portfolio of solutions, Nasdaq enables customers to plan, optimize
and execute their business vision with confidence, using proven
technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 90
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to 3,800 total listings with a market
value of $11 trillion. To learn more, visit:
http://business.nasdaq.com
-NDAQA-
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Apr 2024 to May 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From May 2023 to May 2024